Bioelectronics Corp (BIEL)

[3331]

Do the results of the following study satisfactorily meet the requirements of the No Pain Act: A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel OTC Neuromodulation Therapy
First published: 30 September 2019
https://doi.org/10.1155/2019/3154194

Copilot:
The NOPAIN Act requires that non-opioid pain management treatments demonstrate the ability to replace or reduce opioid consumption through clinical trials or data published in peer-reviewed journals.

The study you mentioned, “A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel OTC Neuromodulation Therapy,” published in Pain Research and Management, evaluates the effectiveness of an over-the-counter neuromodulation device for chronic pain sufferers. This study involved 240 participants and reported significant reductions in pain levels and medication use, including opioids.

Given that the study provides clinical data published in a peer-reviewed journal and demonstrates a reduction in opioid consumption, it appears to meet the requirements of the NOPAIN Act.